Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Geng LN, Bonilla H, Hedlin H, Jacobson KB, Tian L, Jagannathan P, Yang PC, Subramanian AK, Liang JW, Shen S, Deng Y, Shaw BJ, Botzheim B, Desai M, Pathak D, Jazayeri Y, Thai D, O'Donnell A, Mohaptra S, Leang Z, Reynolds GZM, Brooks EF, Bhatt AS, Shafer RW, Miglis MG, Quach T, Tiwari A, Banerjee A, Lopez RN, De Jesus M, Charnas LR, Utz PJ, Singh U. Nirmatrelvir-Ritonavir and Symptoms in Adults With Postacute Sequelae of SARS-CoV-2 Infection: The STOP-PASC Randomized Clinical Trial. JAMA Intern Med. 2024 Sep 01; 184(9):1024-1034.
-
Vecchio F, Carr? A, Korenkov D, Zhou Z, Apaolaza P, Tuomela S, Burgos-Morales O, Snowhite I, Perez-Hernandez J, Brandao B, Afonso G, Halliez C, Kaddis J, Kent SC, Nakayama M, Richardson SJ, Vinh J, Verdier Y, Laiho J, Scharfmann R, Solimena M, Marinicova Z, Bismuth E, Lucidarme N, Sanchez J, Bustamante C, Gomez P, Buus S, You S, Pugliese A, Hyoty H, Rodriguez-Calvo T, Flodstrom-Tullberg M, Mallone R. Coxsackievirus infection induces direct pancreatic ? cell killing but poor antiviral CD8+ T cell responses. Sci Adv. 2024 Mar 08; 10(10):eadl1122.
-
Pasquero S, Gugliesi F, Biolatti M, Dell'Oste V, Albano C, Bajetto G, Griffante G, Trifir? L, Brugo B, Raviola S, Lacarbonara D, Yang Q, Sudeshna S, Barasa L, Haniff H, Thompson PR, Landolfo S, De Andrea M. Citrullination profile analysis reveals peptidylarginine deaminase 3 as an HSV-1 target to dampen the activity of candidate antiviral restriction factors. PLoS Pathog. 2023 Dec; 19(12):e1011849.
-
Faust JS, Kumar A, Shah J, Khadke S, Dani SS, Ganatra S, Sax PE. Oral Nirmatrelvir and Ritonavir for Coronavirus Disease 2019 in Vaccinated, Nonhospitalized Adults Aged 18-50 Years. Clin Infect Dis. 2023 11 11; 77(9):1257-1264.
-
Qaseem A, Yost J, Abraham GM, Andrews R, Jokela JA, Miller MC, Humphrey LL, Dunn A, Haeme R, Lee R, Saini SD, Tschanz CMP, Etxeandia-Ikobaltzeta I, Harrod C, Shamliyan T, Umana K. Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2). Ann Intern Med. 2023 10; 176(10):1396-1404.
-
Dahal S, Clayton K, Cabral T, Cheng R, Jahanshahi S, Ahmed C, Koirala A, Villasmil Ocando A, Malty R, Been T, Hernandez J, Mangos M, Shen D, Babu M, Calarco J, Chabot B, Attisano L, Houry WA, Cochrane A. On a path toward a broad-spectrum anti-viral: inhibition of HIV-1 and coronavirus replication by SR kinase inhibitor harmine. J Virol. 2023 10 31; 97(10):e0039623.
-
Barasa L, Chaudhuri S, Zhou JY, Jiang Z, Choudhary S, Green RM, Wiggin E, Cameron M, Humphries F, Fitzgerald KA, Thompson PR. Development of LB244, an Irreversible STING Antagonist. J Am Chem Soc. 2023 09 20; 145(37):20273-20288.
-
Karasz A, Merchant K, Arnsten J, Feinberg J, Kim AY, Lum PJ, McKee MD, Mehta SH, Meissner P, Norton BL, Page K, Pericot-Valverde I, Singh R, Stein E, Taylor LE, Tsui JI, Wagner K, Litwin A. A Video-Observed Treatment Strategy to Improve Adherence to Treatment Among Persons Who Inject Drugs Infected With Hepatitis C Virus: Qualitative Study of Stakeholder Perceptions and Experiences. J Med Internet Res. 2023 06 02; 25:e38176.
-
Broekema N, Mertens ME, Angelova M, Orzalli MH, Oh HS, Knipe DM. Herpes simplex virus infected cell protein 8 is required for viral inhibition of the cGAS pathway. Virology. 2023 08; 585:34-41.
-
Gressier E, Schulte-Schrepping J, Petrov L, Brumhard S, Stubbemann P, Hiller A, Obermayer B, Spitzer J, Kostevc T, Whitney PG, Bachem A, Odainic A, van de Sandt C, Nguyen THO, Ashhurst T, Wilson K, Oates CVL, Gearing LJ, Meischel T, Hochheiser K, Greyer M, Clarke M, Kreutzenbeck M, Gabriel SS, Kastenm?ller W, Kurts C, Londrigan SL, Kallies A, Kedzierska K, Hertzog PJ, Latz E, Chen YE, Radford KJ, Chopin M, Schroeder J, Kurth F, Gebhardt T, Sander LE, Sawitzki B, Schultze JL, Schmidt SV, Bedoui S. CD4+ T cell calibration of antigen-presenting cells optimizes antiviral CD8+ T cell immunity. Nat Immunol. 2023 06; 24(6):979-990.